Form 4: Decheng Capital Reduces BeyondSpring Stake

Decheng Capital, a 10% owner and director-affiliated entity, reported sales of BeyondSpring Inc. ordinary shares over three days in early October 2025.

Summary

• Decheng Capital China Life Sciences USD Fund III, L.P., a 10% owner and director-affiliated entity of BeyondSpring Inc. (BYSI), reported sales of ordinary shares.
• On September 30, 2025, 4,464 ordinary shares were sold at a weighted average price of $1.81 per share, with prices ranging from $1.80 to $1.83.
• On October 1, 2025, 2,601 ordinary shares were sold at a weighted average price of $1.80 per share, with prices ranging from $1.785 to $1.81.
• On October 2, 2025, 600 ordinary shares were sold at a weighted average price of $1.73 per share, with prices ranging from $1.72 to $1.74.
• These transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following these transactions, Decheng Capital China Life Sciences USD Fund III, L.P. beneficially owns 1,838,096 ordinary shares.
• Additionally, Decheng Capital China Life Sciences USD Fund II, L.P. beneficially owns 1,617,409 ordinary shares, and Decheng Capital Global Healthcare Fund (Master), LP beneficially owns 891,734 ordinary shares.

Sentiment

Score: 5

Explanation: While the sales represent a reduction in stake by a significant insider, the transactions were executed under a Rule 10b5-1 plan, suggesting they were pre-scheduled and not necessarily indicative of new negative developments. However, any reduction by a 10% owner and director-affiliated entity warrants attention, leading to a neutral to slightly negative sentiment.

Negatives

• A significant insider, Decheng Capital (a 10% owner and director-affiliated entity), reduced its stake in BeyondSpring Inc. by selling a total of 7,665 ordinary shares.
• The sales occurred at slightly decreasing weighted average prices over the three-day period, from $1.81 to $1.73.

Risks

• Insider selling by a major shareholder and director-affiliated entity, even if pre-planned, can be perceived negatively by the market and may signal a lack of conviction or strategic rebalancing.

Future Outlook

This filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider transactions, particularly by significant shareholders and director-affiliated entities, are closely watched in the biotechnology and pharmaceutical sectors as they can sometimes signal management's confidence or lack thereof in the company's prospects. However, sales under a 10b5-1 plan are typically pre-scheduled and not necessarily indicative of new, material non-public information.

Related Party Transactions

• The reported sales are related party transactions as they involve Decheng Capital, a 10% owner and entity affiliated with a director (Dr. Cui), selling shares of BeyondSpring Inc.

Stakeholder Impact

• Shareholders may interpret the insider selling as a signal, potentially leading to increased scrutiny of the company's near-term prospects, despite the sales being pre-planned under a 10b5-1 plan.

Key Dates

Recommendation

The sales by Decheng Capital, a 10% owner and director-affiliated entity, were conducted under a pre-arranged Rule 10b5-1 plan. While this mitigates concerns about opportunistic selling based on new material non-public information, it still represents a reduction in a significant insider's stake. Investors should monitor future filings and company performance, but this specific event, being pre-planned, does not immediately warrant a strong buy or sell action without further context.

Keywords

BeyondSpring Inc., BYSI, Decheng Capital, Insider Selling, Form 4, Share Sale, 10b5-1 Plan, Beneficial Ownership